Video

Taking a Closer Look at PCSK9 Part 2

Author(s):

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

Jennifer Robinson, MD, MPH, from the University of Iowa discussed how the landscape could change with these new drugs and what it could mean to overall patient care at the American College of Cardiology's Annual Scientific Sessions and Expo in San Diego.

Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
© 2024 MJH Life Sciences

All rights reserved.